TD Cowen has formally taken over coverage of Insulet Corporation (NASDAQ: PODD), assigning a Hold rating and setting a price target of $294.00. That target sits close to InvestingPro’s Fair Value assessment. Insulet shares are trading at $271.31, while analyst targets across the market span from $274 up to $450.
The coverage change coincided with a personnel shift at Cowen - Matthew Blackman assumed coverage responsibilities from Josh Jennings. With that transition, the firm revised its view on the stock to Hold from the prior rating.
Cowen’s report acknowledged that Insulet is experiencing meaningful commercial momentum. The research note highlights Insulet’s O5 product as "capturing patients at an outsized rate, driving top-tier growth." That observation is consistent with the company’s reported 27.1% revenue increase over the past twelve months and a five-year compound annual growth rate in revenue of 23%.
Alongside product traction, TD Cowen pointed to Insulet’s relative strengths in form factor and pharmacy distribution as competitive advantages. The research team, however, emphasized that competitive dynamics could shift, writing that "the world is not static and the advantages vs. peers likely will narrow." Taken together, Cowen characterized the risk/reward as offering only "modest upside ahead" for the medical device maker despite the visible product pipeline and continuing growth opportunities.
Third-party data referenced by the research shows Insulet’s favorable financial metrics. InvestingPro records a "GREAT" overall financial health score of 3.2 for the company and a gross profit margin of 70.9%.
Several other analyst actions and company updates were noted in recent coverage:
- PricewaterhouseCoopers LLP (PwC) has been appointed Insulet’s independent registered public accounting firm for the fiscal year ending December 31, 2026, replacing Grant Thornton LLP after a competitive selection process. Grant Thornton will continue to conduct the company’s 2025 audit.
- UBS has maintained its Buy rating on Insulet and left its price target at $400, citing what it described as a favorable risk/reward profile heading into 2026.
- BofA Securities trimmed its price target on Insulet to $203 from $214 while keeping a Buy rating, signaling a reassessment of valuation assumptions.
- Evercore ISI initiated coverage with an Outperform rating and a $370 price target, pointing to Insulet’s leadership position in the insulin pump market.
- Bernstein expressed a strong outlook for diabetes technology stocks following its 5th Annual Diabetes Disruptor Conference.
InvestingPro also offers tools for investors seeking additional analysis. The platform’s Fair Value calculator—built from a mix of 17 valuation models—was cited as a means to assess whether PODD represents a bargain at current levels, and InvestingPro promotes additional tips and comprehensive financial data available through its Pro Research Report.
Overall, Cowen’s initiation of coverage and revised rating underline a view that Insulet’s recent growth and product adoption are material but that the path to substantially higher valuation may be limited absent further changes in the competitive landscape or new catalysts.